Gastric & duodenal ulcer; reflux esophagitis (erosive esophagitis). Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin or NSAIDs administration. Adjunct to H. pylori eradication associated w/ gastric & duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, stomach after endoscopic resection of early stage cancer, or H. pylori gastritis.
Adult Gastric ulcer 20 mg once daily for up to 8 wk. Duodenal ulcer 20 mg once daily for up to 6 wk. Reflux esophagitis (erosive esophagitis) 20 mg once daily up to 4 wk. May be continued up to 8 wk if treatment is insufficient. Prevention of recurrence of gastric & duodenal ulcer during low-dose aspirin & NSAID administration 10 mg once daily. Adjunct to H. pylori eradication Vonoprazan 20 mg + amoxicillin hydrate 750 mg + clarithromycin 200 mg bid for 7 days or physician judgment. Alternatively, vonoprazan 20 mg + amoxicillin hydrate 750 mg + metronidazole 250 mg bid for 7 days may be used if other treatment fails.
Discontinue treatment in patients who have evidence of liver function abnormalities or if they develop signs or symptoms suggestive of liver dysfunction. Concomitant use w/ drugs for which absorption is dependent on acidic intragastric pH. Does not preclude gastric malignancy. Renal & hepatic disorders. Pregnancy & lactation. Childn <18 yr. Elderly.
May interfere w/ the absorption of drugs whose bioavailability is pH-dependent (eg, atazanavir & nelfinavir). Increased blood conc w/ strong CYP3A4 inhibitors [eg, clarithromycin (no dose adjustment of Vocinti is considered necessary when concomitantly used)]; w/ clarithromycin & amoxicillin regimen.
A02BC08 - vonoprazan ; Belongs to the class of potassium-competitive acid blocker. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
